Результаты поиска

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes.

Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow microenvironment has led to the development of new drugs to treat MM. This explosion of new and highly effective drugs has led to dramatic advances in the management of MM and underscores the need for supportive care. Impressive and deep response rates to chemotherapy, monoclonal antibodies, and small molecule drugs provide hope of a cure or prolonged remission for the majority of individuals. For most patients, long-term, continuous therapy is often required to suppress the malignant plasma cell clone, thus

Совпадение в полном тексте источника
… fatigue | Bortezomib (more common with IV than SC) | •Educate patient on adequate hydration, careful position changes, and to report worsening of the symptom Prolonged QT-c interval | Palpitations; or may be asymptomatic | HDAC-I panobinostat, vorinostat | • Avoid medications (such as levofloxacin, ondansetron …

Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.

Atrial fibrillation (AF) is the most frequent cardiovascular complication after hematopoietic stem cell transplantation (HSCT) and is linked to higher short-term and long-term morbidity and mortality. AF occurring within 30 days post-HSCT reflects an interplay of peri-transplant triggers, conditioning-related myocardial injury, systemic inflammation and infection, rapid fluid shifts with atrial stretch, and electrolyte disturbances. Beyond 30 days, AF is driven by chronic inflammation and graft-vs.-host disease, metabolic dysregulation from immunosuppression, and cumulative cardiotoxic cancer

Совпадение в полном тексте источника
… Rhythm control medications carry risks of QT prolongation and drug–drug interactions in the setting of chemotherapy, antifungals, and supportive medications (e.g., ondansetron). …

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double-blind, placebo-controlled Phase III TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression-free survival versus placebo-Rd (median: 20·6 vs. 14·7 months; hazard

Совпадение в полном тексте источника
… The most commonly prescribed anti‐emetics were ondansetron and metoclopramide. …

Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the hellenic cardiac society.

Advances in cancer therapeutics have significantly improved patient survival; however, cardiotoxic effects-including arrhythmias-have emerged as a growing clinical concern. This expert opinion, developed by the Working Groups on Cardio-Oncology and Electrophysiology of the Hellenic Cardiological Society, aims to raise awareness of the increasing burden of arrhythmias in cancer patients and survivors. This document explores the multifactorial etiology of arrhythmias in this population, including patient-related factors, the direct effects of malignancy, and the arrhythmogenic potential of thera

Совпадение в полном тексте источника
… Supportive medications that are frequently given to cancer patients and may interact with cardiological medications by prolonging QT interval include antiemetics e.g. ondansetron, granisetron, dolasetron, antihistaminics e.g. astemizole, diphenhydramine, loratadine, terfenadine and antimicrobials e.g …

Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review.

The response to medications in children differs not only in comparison to adults but also between children of the different age groups and according to the disease. This is true for anti-infectives that are widely prescribed in children with malignancy. In the absence of pharmacokinetic/pharmacodynamic paediatric studies, dosage is frequently based on protocols adapted to adults. After a short presentation of the drugs, we reviewed the population pharmacokinetic studies available for glycopeptides (vancomycin and teicoplanin, n = 5) and antifungals (voriconazole, posaconazole, and amphotericin

Совпадение в полном тексте источника
… exponential function, MEDcentred) | WT (linear function, MEDcentred) | None Covariates tested without significant effect on PK parameters | Age, height, gender, diagnosis, history of prior bone marrow transplant, coadministration of total parenteral nutrition, co-medications: acyclovir, cyclosporin, ondansetron …

Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review.

IntroductionWith the exponential rise in global cancer incidence, the surge in demand for palliative care has outstripped capacity, limiting patients' access to quality and holistic palliative care, especially in low- and middle-income countries. Despite an upturn in research activity, evidence in palliative care remains limited, given its complexity as well as the shortage of standardised quality indicators (QIs) and patient outcome measures (POMs). The objective of this systematic review is to assess the QIs and POMs used to evaluate palliative care service on aggregated and individual level

Совпадение в полном тексте источника
… Ondansetron administration by hypodermoclysis site was 3× more likely to have an adverse effect compared to not using this drug. A protective factor was evident with administration of 0.9% sodium chloride which contributed to the reduction of complications. …

From bench to bedside: the application of cannabidiol in glioma.

Glioma is the most common malignant tumor in central nervous system, with significant health burdens to patients. Due to the intrinsic characteristics of glioma and the lack of breakthroughs in treatment modalities, the prognosis for most patients remains poor. This results in a heavy psychological and financial load worldwide. In recent years, cannabidiol (CBD) has garnered widespread attention and research due to its anti-tumoral, anti-inflammatory, and neuroprotective properties. This review comprehensively summarizes the preclinical and clinical research on the use of CBD in glioma therapy

Совпадение в полном тексте источника
… A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew) Psychopharmacology. 2004;174(2):254–259. doi: 10.1007/s00213-003-1739-9. 15. …

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Selinexor: Targeting a novel pathway in multiple myeloma.

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin-1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour suppressor proteins. Inhibition of this process has demonstrated substantial antimyeloma activity in preclinical studies, both alone and in combination with established MM therapeutics. Based on a clinical trial programme encompassing multiple combination regimens, selinexor-based therapy has been approved for t

Совпадение в полном тексте источника
… of symptoms for ≥1 cycle Consider starting at lower dose (40–60 mg) and escalate to 100 mg as tolerated Prophylaxis | | GI toxicity | Provide prophylactic antiemetics; 5‐HT3 receptor antagonist and other anti‐nausea agents prior to treatment | Combination of olanzapine, 5‐HT3 receptor antagonists (ondansetron …

Cancer in pregnancy: FIGO Best practice advice and narrative review.

Cancer during pregnancy is relatively rare. The incidence is underestimated due to the lack of international registries covering both high-income and low- and middle-income countries, and is expected to rise with increasing maternal age and increasing global adoption of cell-free DNA testing for aneuploidy. Physiological changes during pregnancy often make the diagnosis challenging and delayed. Lack of experience and knowledge about this condition may also contribute to late diagnosis, suboptimal management, and occasionally inadvertent fetal and/or maternal harm. The principles of cancer mana

Совпадение в полном тексте источника
… 1st trimester in some malignant melanoma cases Supportive and other treatments Supportive medical treatment, with or without additional psychological support, is an integral part of cancer management during pregnancy. 45 Antiemetics such as metoclopramide and serotonin receptor antagonists (e.g. ondansetron …

Safety of solid oncology drugs in older patients: a narrative review.

The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments f

Совпадение в полном тексте источника
… benefit–risk of treatments | 42 QT prolongation | - Common with kinase inhibitors (one in three molecules) and endocrine therapies - Increased risk of QT prolongation, rhythm disturbances (Torsades de Pointes), and sudden death in older patients, due to drug-related risks - Supportive care drugs such as ondansetron …

Clinical Efficacy and Potential Mechanisms of Acupoint Stimulation Combined With Chemotherapy in Combating Cancer: A Review and Prospects.

Although chemotherapy is the first-line treatment strategy for a variety of tumors, its side effects have limited its efficacy. This review summarizes the progress on the use of acupoint stimulation to combat chemotherapy-associated side effects, including chemotherapy-induced peripheral neuropathy (CIPN), cognitive impairment (CICI), and gastrointestinal toxicity (GI), as well as myelosuppression and immunosuppression. It was found that acupoint stimulation attenuated CIPN and GI by modulating the 5-hydroxytryptamine system in dorsal root ganglia, the dorsal horn of the spinal cord, and the d

Совпадение в полном тексте источника
… LA (n = 8) | Sham acupuncture (n = 10) | CV10, CV12; bilateral: PC6, LI4, SP6, ST36, BL20 | 660 nm, 30 mw, 3 joules, 1 min/point, 6 min, 5 days | Scale of the national cancer institute intensity of nausea↓ Kulthida ( 41 ) | Yes, RCT | Jadad, 4 | Gynecologic cancer patients | Acupuncture (n = 35) | Ondansetron …

Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics.

Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with an extensive history of medical use spanning thousands of years. Interest in the therapeutic potential of CBD has increased in recent years, including its anti-tumour properties in various cancer models. In addition to the direct anticancer effects of CBD, preclinical research on numerous cannabinoids, including CBD, has highlighted their potential use in: (i) attenuating chemotherapy-induced adverse effects and (ii) enhancing the efficacy of some anticancer drugs. Therefore, CBD is ga

Совпадение в полном тексте источника
… A Comparative Analysis of the Potential of Cannabinoids and Ondansetron to Suppress Cisplatin-Induced Emesis in the Suncus Murinus (House Musk Shrew) Psychopharmacology. 2004;174:254–259. doi: 10.1007/s00213-003-1739-9. 66. …

Review of oncological emergencies in small animal patients.

Oncological emergencies can occur at any time during the course of a malignancy and need to be recognized promptly to maximize successful outcomes. Emergencies are characterized as chemotherapy-induced, paraneoplastic syndromes, or directly related to the neoplasm. Prompt identification with treatment of these emergencies can prolong survival and improve quality of life, even in the setting of terminal illness. This review aims to educate the reader on the pathophysiology, clinical presentation and treatment of some of these emergencies, and to review the current veterinary literature to help

Совпадение в полном тексте источника
… Commonly used antiemetics include maropitant and ondansetron. For patients experiencing severe GI side effects, intravenous fluid therapy is recommended. …

Oral Presentation

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Tramadol, Ondansetron, Hyoscine, Haloperidol and Ranitidine injections along with Lorazepam tablets (singly packed and labelled well) packed with a 23 gauge butterfly cannula, an alcohol swab and syringes in a seal proof package along with an anticipatory prescription, phone helpline number and video …

Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.

Doxorubicin (DOX), a widely used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations that induce apoptosis, topoisomerase II inhibition, and histone eviction. Despite its wide therapeutic efficacy in solid tumors, DOX often induces drug resistance and cardiotoxicity. It shows limited intestinal absorption because of low paracellular permeability and P-glycoprotein (P-gp)-mediated efflux. We reviewed various parenteral DOX formulations, such as liposomes, polymeric micelles, polymeric nanopar

Совпадение в полном тексте источника
… Dose-independent pharmacokinetics of ondansetron in rats: Contribution of hepatic and intestinal first-pass effects to low bioavailability Biopharm. Drug Dispos. 2008 29 414 426 10.1002/bdd.628 18697186 10. Rivankar S. An overview of doxorubicin formulations in cancer therapy J. Cancer Res. …

Emergency Care

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs.

AbstractThe treatment paradigm for lymphoma, a highly heterogeneous group of hematologic malignancies, has been revolutionized by the development of therapies targeting oncogenic signaling pathways. This shift from conventional chemotherapy to precision medicine is driven by a deep molecular understanding of the pathways that govern lymphoma cell survival and proliferation. This review comprehensively surveys the landscape of these targeted therapies, from fundamental molecular mechanisms to clinical breakthroughs. We first dissect the molecular architecture of key oncogenic drivers, covering

Совпадение в полном тексте источника
… For example, nausea is typically managed with a prophylactic antiemetic regimen, often including a 5-HT3 receptor antagonist (e.g., ondansetron) combined with olanzapine or a neurokinin-1 receptor antagonist for patients at high risk. …

Резюме МКАРЕ 2023 77th Национальный конгресс " СИААРТИ "

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… In pre-anesthesia, premedication was given iv with ondansetron 4 mg and dexamethasone 4 mg while magnetic beads were positioned on the surface of both ears’ skin, in antiemetic points (Figure 1). … Acupressure Versus Ondansetron Usage for Postoperative Nausea and Vomiting After Gynecologic Surgeries. Cureus. March 2023 Fig. 1 (abstract A16). …

ESCP 36th European Symposium on Clinical Pharmacy ‘Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience’, Istanbul, Turkey 25–27 October 2007; Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.